X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
The Company plans to use proceeds to complete an international Phase 2 double-blind, randomized, placebo-controlled clinical trial of its investigational drug Valproic Acid (CT-010) for the treatment of uncontrolled seizures in patients with medically refractory epilepsy.
Lead Product(s): Sodium Valproate
Therapeutic Area: Neurology Product Name: CT-010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lynx1 Capital Management
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 28, 2022
Details:
The Phase 2b, randomized, placebo-controlled, double-blind study is designed to expand on positive results of the ongoing Phase 1b/2a study assessing the safety and efficacy of intracerebroventricular administration of sodium valproate.
Lead Product(s): Sodium Valproate
Therapeutic Area: Neurology Product Name: CT-010
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
The funding will help the company to initiate Phase 2b clinical trial for the treatment of medically refractory epilepsy in 2020.
Lead Product(s): Sodium Valproate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
